Medicine Description prandaglim-plus 25/15 mg
prandaglim plus 30 tablets 25/15 mg is a medication that combines two active ingredients, alogliptin and pioglitazone, to manage type 2 diabetes. Alogliptin functions as a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, which inhibits the enzyme responsible for breaking down incretin hormones. These hormones play a crucial role in glucose metabolism by increasing insulin secretion from the pancreas and decreasing glucagon secretion, thereby reducing hepatic glucose production. Pioglitazone, on the other hand, belongs to the thiazolidinedione class and enhances insulin sensitivity in peripheral tissues, mainly muscle and adipose tissue. This dual action helps in more effective control of blood sugar levels and may lead to improved metabolic parameters in patients with type 2 diabetes.
Indications and Uses of prandaglim plus 30 tablets 25/15 mg
- Management of blood glucose levels in adults with type 2 diabetes
- Reduction of the risk of diabetes-related complications
- Improvement of insulin sensitivity in patients inadequately controlled by diet and exercise
Side Effects of prandaglim plus 30 tablets 25/15 mg
- Weight gain
- Edema
- Upper respiratory tract infections
- Headache
- Gastrointestinal disturbances
- Hypoglycemia when used with other antidiabetic medications
Storage and Handling
Store prandaglim plus tablets in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.
Patient Advice and Precautions
Patients should be advised to monitor their blood sugar levels regularly and report any signs of hypoglycemia. It is essential to adhere to prescribed lifestyle modifications, including diet and exercise. Be aware of potential weight gain and discuss any concerns with your healthcare provider. Regular follow-up appointments are necessary to assess the medication's effectiveness and make any necessary adjustments.